{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-000209","form_type":"8-K","ticker":"ZURA","cik":"0001855644","company_name":"Zura Bio Ltd","filed_at":"2026-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.566253+00:00","generated_at":"2026-05-16T11:50:20.164147+00:00","sec_items":["1.01","1.02","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"confidence":"high","headline":"Zura Bio terminates prior Stone Peach/BAFFX17 agreements, issues 8.66M shares to Athanor Capital","bullets":["Terminated Letter Agreements with Stone Peach and BAFFX17; entered new Athanor Agreement on Dec 29, 2025.","Issued 8,657,402 Class A ordinary shares to Athanor; $7.325M upfront fee and $25M milestone payment on change of control or first regulatory approval.","Athanor receives piggyback registration rights and 2% net sales royalty on tibulizumab (ZB-106) from the Lilly license.","Audit Subcommittee review completed; no financial statement impact or employee misconduct found.","New terms deemed more commercially advantageous; prior agreements voided with broad releases."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-000209","json":"https://secwatch.observer/filing/0001104659-26-000209.json","markdown":"https://secwatch.observer/filing/0001104659-26-000209.md","text":"https://secwatch.observer/filing/0001104659-26-000209.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855644/000110465926000209/0001104659-26-000209-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855644/000110465926000209/tm2531128d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:50:20.164147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}